Corbevax becomes third Covid vaccine to be approved for children in India

Biological E's Corbevax gets DCGI nod based on interim results from phase 2/3 studies

A third Covid-19 vaccine for children has now obtained the Indian drug regulator’s nod. Biological E’s (BE) receptor binding domain (RBD) protein sub-unit vaccine against Covid-19 has been granted an emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI). based on interim results of the ongoing phase-2 and 3 clinical study.

Cadila Healthcare’s ZyCoV-D and Bharat Biotech’s Covaxin are two vaccines that have already been approved in this category. Of these, Covaxin is already in use for vaccinating adolescents 15-17 years. Covaxin got a recommendation for approval to be used in children as young as two year